New hope for lymphoma patients Who've run out of options
NCT ID NCT04875195
Summary
This study tested whether giving the immunotherapy drug pembrolizumab every six weeks could help control two types of lymphoma that had returned or stopped responding to previous treatments. It involved 66 adults with relapsed Hodgkin's lymphoma or primary mediastinal large B-cell lymphoma. The main goal was to see how many patients' cancers shrank or disappeared after receiving this treatment schedule.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Almazov National Medical Research Centre ( Site 0807)
Saint Petersburg, Sankt-Peterburg, 197341, Russia
-
Ankara University Department of Hematology, Clinical Research Unit ( Site 1101)
Ankara, 06100, Turkey (Türkiye)
-
Anne Arundel Medical Center-Anne Arundel Oncology and Hematology ( Site 0125)
Annapolis, Maryland, 21401, United States
-
Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO-EMATOLOGIA I ( Site 0507)
Palermo, Sicily, 90146, Italy
-
CNPE Regional Center of Oncology ( Site 1305)
Kharkiv, Kharkivs’ka Oblast’, 61070, Ukraine
-
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 0401)
Dijon, Cote-d Or, 21000, France
-
Cross Cancer Institute ( Site 0207)
Edmonton, Alberta, T6G 1Z2, Canada
-
Ege University Medicine of Faculty ( Site 1105)
Bornova, İzmir, 35100, Turkey (Türkiye)
-
Fakultni nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0302)
Brno, Brno-mesto, 625 00, Czechia
-
Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0304)
Hradec Králové, 500 05, Czechia
-
Fakultni nemocnice Kralovske Vinohrady-Interni hematologicka klinika ( Site 0303)
Prague, Praha 10, 100 34, Czechia
-
Fondazione IRCCS Policlinico San Matteo ( Site 0509)
Pavia, Lombardy, 27100, Italy
-
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1701)
Barretos, São Paulo, 14784-400, Brazil
-
Groote Schuur Hospital ( Site 0906)
Cape Town, Western Cape, 7925, South Africa
-
Gustave Roussy ( Site 0402)
Villejuif, Île-de-France Region, 94800, France
-
Hospital Erasto Gaertner ( Site 1703)
Curitiba, Paraná, 81520-060, Brazil
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0503)
Naples, 80131, Italy
-
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site
Torrance, California, 90502, United States
-
Moscow City Clinical Hospital S.P. Botkin ( Site 0803)
Moscow, Moscow, 125284, Russia
-
National Cancer Institute ( Site 1303)
Kyiv, Kyivska Oblast, 03022, Ukraine
-
Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 0902)
Centurion, Gauteng, 0044, South Africa
-
Pratia MCM Krakow ( Site 0064)
Krakow, Lesser Poland Voivodeship, 30-510, Poland
-
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-Oddzial Hematologii i Transplantacji S
Poznan, Greater Poland Voivodeship, 61-848, Poland
-
The National Medico-Surgical Center N.I. Pirogov ( Site 0801)
Moscow, Moscow, 105203, Russia
-
Tulane Medical Center ( Site 0110)
New Orleans, Louisiana, 70112, United States
-
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0063)
Gdansk, Pomeranian Voivodeship, 80-952, Poland
-
Wits Clinical Research ( Site 0904)
Johannesburg, Gauteng, 1864, South Africa
Conditions
Explore the condition pages connected to this study.